ctDNA as a Biomarker for Treatment Response in HNSCC

Launched by THE NETHERLANDS CANCER INSTITUTE · May 16, 2018

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 18 years of age
• • Stage II-IV carcinoma of the larynx, hypopharynx, oral cavity or HPV negative oropharynx or stage II-III HPV positive oropharyngeal carcinoma, histologically confirmed according to the American Joint Committee on Cancer (AJCC) staging manual 8th edition
• • Indication for primary curative radiotherapy with or without concurrent radio sensitizer
• • WHO performance status 0-2
• • Signed written IC
• Exclusion Criteria:
• • Metastatic disease
• • Radiotherapy with palliative intent
• • Diagnosis of any other malignancy within 5 years prior to start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, or low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g. surgery, radiation or castration).